![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260916_Weill_Cornell_Technology_and_Modalities-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Weill Cornell Medicine (with Mount Sinai, New York Genome Center, Memorial Sloan Kettering, New York Blood Center)<\/p>\n Event Type<\/strong><\/p>\n Peer-Reviewed Publication<\/p>\n Modality<\/strong><\/p>\n Genotype-Resolved Single-Cell Multiomics of Interferon Alfa Therapy<\/p>\n Target<\/strong><\/p>\n CALR- and JAK2-Mutated Hematopoietic Stem\/Progenitor Cells<\/p>\n Disease Area<\/strong><\/p>\n Essential Thrombocythemia and Polycythemia Vera<\/p>\n A peer-reviewed human study mapped how pegylated interferon alfa changes hematopoietic stem and progenitor-cell behavior in essential thrombocythemia and polycythemia vera. Genotype-resolved single-cell multiomics showed that interferon simultaneously expanded lymphoid progenitors and generated an inflammatory myeloid progenitor state. CALR- or JAK2-mutated stem cells that entered that myeloid trajectory tended to contract, whereas clones resistant to it persisted or expanded. The work offers a mechanistic explanation for why blood counts may improve without equivalent molecular response, but it does not yet establish a prospective response biomarker or a druggable intervention beyond interferon itself.<\/p>\n The study analyzed serial bone-marrow samples from patients in MPN-RC-111 and MPN-RC-112 who received weekly pegylated interferon alfa for at least one year. The main genotype-of-transcriptomes dataset contained 65,452 CD34-positive cells from 24 samples across 13 individuals, including 33,877 baseline and 31,575 treated cells; 72% of cells were genotyped for CALR mutations. Additional chromatin-accessibility experiments examined JAK2-V617F disease. Interferon induced HSC cycling, reduced megakaryocytic and erythroid progenitors, expanded B-lymphoid progenitors, and produced a transcriptionally distinct inflammatory myeloid progenitor population. Across CALR- and JAK2-mutated samples, greater entry of mutated HSCs into that state correlated with clonal depletion, while resistance correlated with clonal persistence or expansion.<\/p>\n One interpretation is that interferon response is governed partly by differentiation competence rather than by simple antiproliferative pressure. This is supported by paired mutated and wild-type cells from the same marrow, longitudinal sampling, orthogonal transcriptomic and chromatin measurements, and the reported relationship between inflammatory myeloid progenitor propensity and clone-size change. It is also consistent with clinical count normalization despite variable molecular response. Against it, the patient cohorts were small, some samples were not paired, and the strongest CALR and JAK2 analyses draw on different assay configurations. A second interpretation is that treatment creates competing beneficial and adverse selection pressures: lymphoid rebalancing and reduced megakaryocytic-erythroid output can improve blood counts, while clones that avoid terminal or inflammatory differentiation retain stem-cell fitness and may dominate the niche. Deliberately forcing HSC differentiation could damage normal reserve, intensify inflammation or select alternative resistant states, and the work contains no intervention that selectively pushes mutant HSCs into the proposed state without affecting wild-type cells.<\/p>\n Essential thrombocythemia and polycythemia vera are chronic myeloproliferative neoplasms commonly driven by JAK2, CALR or MPL mutations that bias blood production toward platelets or erythrocytes and can progress to myelofibrosis or acute leukemia. Interferon alfa activates type 1 interferon signaling, induces HSC cycling and can reduce mutant allele burden in some patients. The reported mechanism links its clinical effect to altered lineage choice and differential exhaustion or persistence of mutant versus wild-type stem cells.<\/p>\n This is a high-importance, directionally uncertain hematology signal. The strongest supported conclusion is mechanistic: interferon reshapes differentiation trajectories, and resistance to a specific myeloid state is associated with clonal fitness. It would be premature to claim a validated response test or a treatment-ready target.<\/p>\n Signal strength:<\/strong> 5\/5 — genotype-resolved evidence connecting interferon mechanism to clonal fitness in treated human marrow. Importance:<\/strong> Uncertain. Confidence:<\/strong> High on facts, based on a peer-reviewed, open-access article with patient-level longitudinal sampling and transparent methods. Interpretation confidence:<\/strong> Moderate, because the mechanistic model is coherent and multi-omic but rests on small heterogeneous cohorts and has not been prospectively validated as a biomarker or intervention.<\/p>\n","protected":false},"excerpt":{"rendered":" A peer-reviewed human study mapped how pegylated interferon alfa changes hematopoietic stem and progenitor-cell behavior in essential thrombocythemia and polycythemia vera. Genotype-resolved single-cell multiomics showed that interferon simultaneously expanded lymphoid progenitors and generated an…<\/p>\n","protected":false},"author":1,"featured_media":3204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[782,115,783],"class_list":["post-3202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-interferon-alfa","tag-myeloproliferative-neoplasms","tag-weill-cornell-medicine"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3202"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3202\/revisions"}],"predecessor-version":[{"id":3219,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3202\/revisions\/3219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3204"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n